BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 11544530)

  • 1. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice.
    Krimpenfort P; Quon KC; Mooi WJ; Loonstra A; Berns A
    Nature; 2001 Sep; 413(6851):83-6. PubMed ID: 11544530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
    Sharpless NE; Bardeesy N; Lee KH; Carrasco D; Castrillon DH; Aguirre AJ; Wu EA; Horner JW; DePinho RA
    Nature; 2001 Sep; 413(6851):86-91. PubMed ID: 11544531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a.
    Krimpenfort P; Ijpenberg A; Song JY; van der Valk M; Nawijn M; Zevenhoven J; Berns A
    Nature; 2007 Aug; 448(7156):943-6. PubMed ID: 17713536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo.
    Sharpless NE; Kannan K; Xu J; Bosenberg MW; Chin L
    Oncogene; 2003 Aug; 22(32):5055-9. PubMed ID: 12902988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
    D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
    Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
    Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
    Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging.
    Matheu A; Pantoja C; Efeyan A; Criado LM; Martín-Caballero J; Flores JM; Klatt P; Serrano M
    Genes Dev; 2004 Nov; 18(22):2736-46. PubMed ID: 15520276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
    D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
    Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF.
    Sarkar-Agrawal P; Vergilis I; Sharpless NE; DePinho RA; Rünger TM
    J Natl Cancer Inst; 2004 Dec; 96(23):1790-3. PubMed ID: 15572761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis].
    Soufir N; Basset-Seguin N
    Bull Cancer; 2001 Nov; 88(11):1061-7. PubMed ID: 11741799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
    Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
    Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
    Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
    Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
    Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
    Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus.
    Gilley J; Fried M
    Oncogene; 2001 Nov; 20(50):7447-52. PubMed ID: 11704876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
    Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
    Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures.
    van Schanke A; van Venrooij GM; Jongsma MJ; Banus HA; Mullenders LH; van Kranen HJ; de Gruijl FR
    Cancer Res; 2006 Mar; 66(5):2608-15. PubMed ID: 16510579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.
    Ackermann J; Frutschi M; Kaloulis K; McKee T; Trumpp A; Beermann F
    Cancer Res; 2005 May; 65(10):4005-11. PubMed ID: 15899789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The latent membrane protein 1 of Epstein-Barr virus and loss of the INK4a locus: paradoxes resolve to cooperation in carcinogenesis in vivo.
    Macdiarmid J; Stevenson D; Campbell DH; Wilson JB
    Carcinogenesis; 2003 Jul; 24(7):1209-18. PubMed ID: 12807717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.